California’s low-cost insulin plans receive $100m manufacturing boost
Pharmaceutical Technology
JULY 15, 2022
The documents state that a partnership with a CMO would be cheaper than the state directly manufacturing insulin. The bill still must pass the Senate, and moreover, how uninsured people with diabetes will deal with steep prices still remains a question. In-house manufacturing the norm. Industry split over the pricing issues.
Let's personalize your content